Cardiovascular Risk Reduction
&
ADVISORY BOARD
Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
Clinical Affiliate Professor of Cardiology, Charles E. Schmidt College of Medicine, Florida Atlantic University; Founder/Chief Medical Officer, Excel Medical Clinical Trials, Boca Raton, Florida
Dr Baum is a graduate of Columbia University College of Physicians and Surgeons and completed training in internal medicine, cardiology, interventional cardiology, and electrophysiology. Dr Baum is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology.
Dr Baum is a past president of the American Society for Preventive Cardiology. He currently sits on the Family Heart Foundation LP(a) Advisory Board. He has published more than 100 peer-reviewed papers and abstracts as well as two books. In 2013, he received Cleveland Heart Lab's Heart Award for lifelong dedication to preventive medicine. In 2019, Dr Baum received Mended Hearts' biennial Dwight Emary Harken Award.
Dr Baum is the founder and chief medical officer of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as principal investigator in more than 100 clinical trials covering a broad band of disease states.
Dr Baum is clinical affiliate professor of cardiology at Florida Atlantic University Medical School and actively consults in clinical lipidology and cardiovascular disease prevention in Boca Raton, Florida.
Disclosures
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Altimmune; Amgen; Madrigal; Novartis; Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Amgen; Boehringer Ingelheim; Eli Lilly; Esperion; Regeneron
Serve(d) on the scientific advisory board for: Altimmune; Amgen; Axcella; Boehringer Ingelheim; Eli Lilly; Esperion; Madrigal; Novartis; Regeneron
Matthew J. Budoff, MD
Professor of Medicine, University of California, Los Angeles; Program Director, Department of Cardiology, Harbor UCLA Medical Center, Torrance, California
Dr Budoff has devoted much of his time over the past 25 years to advancing procedures that can help doctors identify cardiac patients early and place them on a therapeutic path to prevent heart attacks. Dr Budoff works on at least 20 active medical research trials at any given time and is a frequent lecturer on cardiology topics at symposia, congresses, and annual conferences globally. He has authored or coauthored over 800 research papers, seven books, and 45 book chapters.
Disclosures
Matthew J. Budoff, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Amarin Pharma Inc.
Received research grant from: General Electric; Amarin Pharma Inc.
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor, Director of Clinical Research, Department of Primary Care, Touro College of Osteopathic Medicine, Vallejo, California; Diabetologist and Director of Diabetes Services, Solano County Family Health Services, Fairfield, California
Dr Shubrook is a board-certified family physician and fellowship-trained diabetologist. He is a professor and director of clinical research at the Touro College of Osteopathic Medicine in Vallejo, California, where he also serves as director of diabetes services. He completed his medical and fellowship training at Heritage College of Osteopathic Medicine in Athens, Ohio. He serves as an associate editor for Clinical Diabetes. His clinical and educational focus is to better prepare the primary care workforce to help manage people with diabetes and other cardiometabolic diseases.
Disclosures
Jay H. Shubrook, DO, FAAFP, FACOFP, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott; AstraZeneca; Bayer; Eli Lilly; Novo Nordisk
Pam R. Taub, MD, FACC, FASPC
Professor of Medicine, University of California San Diego School of Medicine; Founding Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center, La Jolla, California
Dr Taub is a board-certified cardiologist and founding director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center at UC San Diego. Dr Taub was responsible for all aspects of creating the center, which provides a comprehensive cardiac rehabilitation program for patients with established heart disease.
Her clinical practice focuses on preventive cardiology, lipidology, and women's cardiovascular health. She has extensive clinical trial experience and is active in clinical and translational research. Her research focuses on assessing the impact of behavioral, technological, and pharmacological interventions on cardiometabolic disease. Dr Taub is a federally funded researcher with funding from the National Institutes of Health (principal investigator on R01 grant), Department of Defense, Department of Homeland Security, and American Heart Association.
Dr Taub is widely published (with more than 100 publications) and has authored high-impact publications in top peer-reviewed journals, including Cell Metabolism and the Journal of the American College of Cardiology.
Dr Taub holds multiple leadership positions in professional societies, serving as a fellow and board member for the American Society for Preventive Cardiology. She is a fellow and member of the American College of Cardiology Prevention of CV Disease Section Leadership Council. She also serves on the American Heart Association Council on Clinical Cardiology (Women in Cardiology Committee).
Disclosures
Pam R. Taub, MD, FACC, FASPC, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Esperion Therapeutics; Boehringer Ingelheim; Novo Nordisk; Amarin Corporation; Novartis, Medtronic, Sanofi
Serve(d) as a shareholder for: Epirium Bio
The Cardiovascular Risk Reduction Center of Excellence is a collaboration between the American College of Cardiology and Medscape. Content developed through the partnership, with oversight from the Advisory Board, is labeled as a collaboration.